Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;64(9):1373-81.
doi: 10.1002/acr.21704.

Umbilical cord blood levels of maternal antibodies reactive with p200 and full-length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus

Joanne H Reed  1 , Robert M Clancy, Kristen H Lee, Amit Saxena, Peter M Izmirly, Jill P Buyon
Affiliations

Umbilical cord blood levels of maternal antibodies reactive with p200 and full-length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus

Joanne H Reed et al. Arthritis Care Res (Hoboken). 2012 Sep.

Abstract

Objective: Maternal anti-Ro autoantibodies are associated with cardiac manifestations of neonatal lupus (cardiac NL), yet only 2% of women with this reactivity have an affected child. Identification of a more specific marker would channel intense monitoring to fetuses at greater risk. This study aimed to determine whether autoantibodies against Ro 52 amino acids 200-239 (p200) confer added risk over autoantibodies to full-length Ro 52, Ro 60, or La.

Methods: Anti-Ro-exposed pregnancies resulting in cardiac NL or no cardiac manifestations were identified from the Research Registry for Neonatal Lupus and the PR Interval and Dexamethasone Evaluation study. Umbilical cord (n = 123) and maternal (n = 115) samples were evaluated by enzyme-linked immunosorbent assay.

Results: The frequencies of p200, Ro 52, Ro 60, and La autoantibodies were not significantly different between affected and unaffected children. However, neonatal anti-Ro 52 and Ro 60 titers were highest in cardiac NL and their unaffected siblings compared to unaffected neonates without a cardiac NL sibling. Although both maternal anti-Ro 52 and p200 autoantibodies were less than 50% specific for cardiac NL, anti-p200 was the least likely of the Ro autoantibodies to be false-positive in mothers who have never had an affected child. Titers of anti-Ro 52 and p200 did not differ during a cardiac NL or unaffected pregnancy from the same mother.

Conclusion: Maternal reactivity to p200 does not confer an added risk to fetal conduction defects over full-length Ro 52 or Ro 60 autoantibodies. Mothers who may never be at risk for having an affected child have lower anti-Ro 60 titers and may require less stringent echocardiographic monitoring compared to women with high-titer autoantibodies.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Umbilical cord blood titer of anti-p200, anti-Ro52, anti-Ro60 and anti-La
Reactivity of umbilical cord plasma from neonates with cardiac NL (Group 1), unaffected siblings of neonates with cardiac NL (Group 2), or unaffected neonates with only unaffected siblings (Group 3) against p200 (Ro52 aa 200–239) peptide (A), full length recombinant Ro52 (B), native Ro60 (C), or native La (D). The mean ELISA binding units of duplicate determinations is plotted for each neonate that was considered positive (>3 SD above the median binding units for 28 healthy controls). Cut-offs for positivity are >6.4 for Ro52, >4.5 for p200 and >19 for Ro60 and La. Solid lines represent the median ELISA binding units for each group.
Figure 2
Figure 2. Maternal serum titer of anti-p200, anti-Ro52, anti-Ro60 and anti-La
Reactivity of serum from mothers pregnant with a cardiac NL child (Group 1), an unaffected child born subsequent to a cardiac NL child (Group 2), or an unaffected child and had only unaffected children (Group 3) against p200 peptide (A) full length recombinant Ro52 (B), native Ro60 (C), or native La (D). The mean ELISA binding units of duplicate determinations is plotted for each neonate considered positive (>3 SD above the median binding units for 28 healthy controls). Cut-offs for positivity are >6.4 for Ro52, >4.5 for p200 and >19 for Ro60 and La. Solid lines represent the median ELISA binding units for each group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Izmirly PM, Saxena A, Kim MY, Wang D, Sahl SK, Llanos C, et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation. 2011;124:1927–35. - PMC - PubMed
    1. Buyon JP, Friedman DM. Neonatal Lupus. In: Lahita RG, Tsokos G, Buyon JP, Koike T, editors. Systemic Lupus Erythematosus. 5. San Diego: Academic Press; 2011. pp. 541–67.
    1. Friedman DM, Kim MY, Copel JA, Davis C, Phoon CK, Glickstein JS, et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation. 2008;117:485–93. - PubMed
    1. Friedman DM, Llanos C, Izmirly PM, Brock B, Byron J, Copel J, et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum. 2010;62:1138–46. - PMC - PubMed
    1. Buyon JP, Clancy RM. Neonatal Lupus: Basic Research and Clinical Perspectives. Rheum Dis Clin N Am. 2005;31:299–313. - PubMed

Publication types

MeSH terms

Supplementary concepts